TY - JOUR
T1 - Treatment of pulmonary hypertension: bench to bedside
AU - Springer, Jochen
AU - Lainscak, Mitja
AU - Salobir, Barbara
AU - Lang, Irene M.
PY - 2011
Y1 - 2011
N2 - Pulmonary arterial hypertension is an orphan disease and a model for drug developments over recent years. Expert centers have focused basic science on the pulmonary vasculature and the right ventricle, followed by a direct transfer of innovative concepts to clinical research. Successful examples for translational experimentation are the endothelin receptor antagonists, prostacyclin receptor agonists, and the activators of soluble guanylate cyclase. On the other hand, there have been failures such as vasoactive intestinal peptide, statins, and escitalopram. Several new drugs and gene therapy are under investigation, thus significant advances are anticipated.
AB - Pulmonary arterial hypertension is an orphan disease and a model for drug developments over recent years. Expert centers have focused basic science on the pulmonary vasculature and the right ventricle, followed by a direct transfer of innovative concepts to clinical research. Successful examples for translational experimentation are the endothelin receptor antagonists, prostacyclin receptor agonists, and the activators of soluble guanylate cyclase. On the other hand, there have been failures such as vasoactive intestinal peptide, statins, and escitalopram. Several new drugs and gene therapy are under investigation, thus significant advances are anticipated.
U2 - 10.1016/S0954-6111(11)70004-X
DO - 10.1016/S0954-6111(11)70004-X
M3 - Article
SN - 0954-6111
VL - 105
SP - S7-S11
JO - Respiratory Medicine
JF - Respiratory Medicine
IS - Suppl 1
ER -